Chemi-Luminescence ImmunoAssay (CLIA) for the quantitative determination of antibodies to COVID-19 Virus (SARS-CoV-2) Spike/RBD in human plasma and sera.
The Antibody assay is intended for testing:
(a) health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing anti Spike/RBD antibodies.
(b) normal population for epidemiology studies on presence of potential “protective” Antibodies to SARS-CoV-2 Spike/RBD;
(c) PCR-negative infected individuals, successfully recovered from infection, to assure presence of potentially neutralizing antibodies;
(d) human donors, recovered from COVID-19 infection, positive for anti-Spike/RBD antibodies for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease;
(e) vaccinated individuals to assure a reliable positive immunization with development of anti Spike/RBD antibodies.